Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02750384
Recruitment Status : Terminated (Sponsor strategic decision based on preliminary results)
First Posted : April 25, 2016
Last Update Posted : September 14, 2016
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Medicines for Malaria Venture

Brief Summary:
This is a single-dose, fasting and non-fasting, open-label, randomized, three-regimen, parallel group study in 42 subjects

Condition or disease Intervention/treatment Phase
Healthy Volunteers Bioavailability Drug: DSM265 50% SDD granules Drug: DSM265 25% SDD powder for suspension Phase 1

Detailed Description:

This is a randomized, open label, single dose, parallel group study consisting of 3 groups of 14 subjects each. Subjects will be confined for 3 days followed by outpatient assessments until Day 21. Blood samples for assessment of DSM265 plasma concentrations will be collected for 480 hours after dosing.

This study will compare the relative bioavailability of the oral DSM265 50% spray dried dispersion (SDD) granules with that of a reference 25% SDD powder for suspension formulation, and evaluate the effect of food on the DSM265 50% SDD granules


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: An Assessment of the Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects
Study Start Date : May 2016
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Arm Intervention/treatment
Experimental: 50% SDD granules, fasting
50% spray dried dispersion granules, fasting
Drug: DSM265 50% SDD granules
Single oral dose 400 mg

Active Comparator: 25% SDD powder for suspension, fasting
25% spray dried dispersion powder for suspension, fasting
Drug: DSM265 25% SDD powder for suspension
Single oral dose 400 mg

Experimental: 50% SDD granules, fed
50% spray dried dispersion granules, fed
Drug: DSM265 50% SDD granules
Single oral dose 400 mg




Primary Outcome Measures :
  1. DSM265 maximum observed plasma concentration (Cmax) [ Time Frame: Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours ]
  2. DSM265 time to Cmax (Tmax) [ Time Frame: Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours ]
  3. DSM265 observed concentration at 168 hours after dosing (C168) [ Time Frame: Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours ]
  4. DSM265 apparent terminal phase elimination rate constant (β) [ Time Frame: Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours ]
  5. DSM265 terminal elimination half-life (t1/2) [ Time Frame: Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours ]
  6. DSM265 area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUCt) [ Time Frame: Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours ]
  7. DSM265 area under the plasma concentration-time curve from time 0 to infinity (AUC∞) [ Time Frame: Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours ]

Secondary Outcome Measures :
  1. safety evaluations [ Time Frame: Pre-dose and Days 1, 2, 4, 6, 8, 10, 14, and 21 ]
    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female subjects of non-child bearing potential:

    • surgically sterile (by hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy or bilateral tubal ligation) OR
    • postmenopausal (without use of hormonal contraceptive and spontaneous amenorrhea for 12 months and follicle stimulating hormone > 40 IU/mL age appropriate for menopause and no other medical explanation for amenorrhea)
  • Males:

    • If he (including those who have had a vasectomy) is sexually active with female partner(s) of childbearing potential, he must agree, from Day 1 through 120 days after the dose of study drug to practice the continuous acceptable methods of contraception with his partner(s).
    • If he has a female partner who is postmenopausal or permanently sterile, the male subject must agree to use condoms from Day 1 through 120 days after the dose of study drug
  • Females must have negative pregnancy tests:

    • at Screening within 28 days prior to initial study drug administration, and
    • prior to dosing on Study Day -1
  • Body Mass Index at least 18.0 and less than / equal to 29.9. Body weight must be >50 kg
  • General good health, based on medical history, physical examination, vital signs, laboratory profile and Electrocardiogram
  • Voluntarily sign and date each informed consent, approved by an Institutional Review Board, prior to any screening or study procedures

Exclusion Criteria:

  • Female who is pregnant, breastfeeding or is considering becoming pregnant during the study or for approximately 60 days after the dose of study drug
  • Male who is considering fathering a child or donating sperm during the study or for 120 days after the last dose of study drug
  • History of significant sensitivity to any drug
  • History of epilepsy, any clinically significant cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness
  • History of gastric surgery (except phyloromoyotomy for pyloric stenosis during infancy), vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption
  • Requirement for any over-the-counter or prescription medication, vitamins or herbal supplements, except contraceptives or hormone replacement therapy for females, on a regular basis
  • Use of any medication, vitamins / herbal supplements except contraceptives or hormone replacement therapy for females, within 2 weeks prior to study drug administration or within 5 half-lives, whichever is longer
  • Receipt of any drug by injection within 30 days or 5 half-lives, whichever is longer, prior to study drug administration, except parenteral hormonal contraceptives for females
  • Receipt of any investigational product within 6 weeks prior to study drug administration or 5 half-lives, whichever is longer
  • Recent (6-month) history of drug or alcohol abuse
  • Consumption of alcohol within 72 hours prior to study drug administration
  • Consumption of grapefruit or grapefruit products, Seville oranges, starfruit, or products containing any of these ingredients, and/or quinine/tonic water from 7 days prior to study drug administration
  • Use of tobacco or nicotine-containing products within 6 months before study drug administration
  • Positive for hepatitis A virus immunoglobulin M, hepatitis B surface antigen or hepatitis C virus antibody or HIV antibodies. Negative HIV status will be confirmed at Screening and results will be maintained confidentially
  • Positive screen for drugs of abuse, or alcohol or cotinine or positive and clinically significant urine adulterants test
  • Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product in 8 weeks prior to study drug administration
  • Current enrollment in another clinical study
  • Previous enrollment in this study
  • Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive DSM265

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02750384


Locations
Layout table for location information
United States, Illinois
AbbVie Clinical Pharmacology Research Unit (ACPRU)
Grayslake, Illinois, United States, IL 60030
Sponsors and Collaborators
Medicines for Malaria Venture
AbbVie
Investigators
Layout table for investigator information
Principal Investigator: David , Carter, MD AbbVie

Layout table for additonal information
Responsible Party: Medicines for Malaria Venture
ClinicalTrials.gov Identifier: NCT02750384     History of Changes
Other Study ID Numbers: B16-963
MMV_DSM265_16_01 ( Other Grant/Funding Number: The Medicines for Malaria Venture )
First Posted: April 25, 2016    Key Record Dates
Last Update Posted: September 14, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No